10 March 2021 -  Pembrolizumab was listed in the Cancer Drugs Fund for this indication.

Pembrolizumab with pemetrexed and platinum chemotherapy is recommended as an option for adults with untreated, metastatic, non-squamous non-small-cell lung cancer whose tumours have no epidermal growth factor receptor positive or anaplastic lymphoma kinase positive mutations. 

This is only if pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the disease progresses and Merck provides pembrolizumab according to the commercial arrangement.

Read NICE Technology Appraisal Guidance for pembrolizumab